Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.47-8.20%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for JSPR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
reduce net loss to about -$1.17M by Q1 2026 | Net loss dropped from $27M to $1M. | Improving | net loss stays above -$1.17M by 2026-Q1 | Net income: $-2.76M FY2026-Q2; GAAP. Published target: net loss <= -$1.17M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-2,760,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
JSPR is a speculative clinical-stage healthcare company, not a proven earnings compounder: it is loss-making and carries high risk. The thesis is intact, but confidence is low and management has been volatile, including a recent CEO transition.
The evidence snapshot provides no valuation or market-expectations measures, so whether JSPR looks cheap or expensive versus peers cannot be assessed. The thesis therefore depends more on clinical and regulatory progress than on a documented expectations gap.
Near term, JSPR remains loss-making, though its operating loss narrowed from $10.952 million in the first quarter of 2026 to $9.207 million in the second. The October update reported that 18 patients were enrolled in the KP-104 IgAN cohort and enrollment finished on schedule, but the company has not yet shown revenue-generating delivery; a next-quarter earnings miss risk is elevated.
Over the multi-year view, the thesis hinges on KP-104 progress, advancement of briquilimab toward a potential BLA, and whether KP-701 reaches first-in-human studies after a planned Phase 1 filing. In the near term, weaker jobs data could weigh on healthcare names, while results and guidance from VRTX, REGN, and MRNA may signal whether the sector tailwind continues.
For the next one to three years, JSPR presents an intact but low-confidence clinical-development thesis, with scheduled enrollment progress set against continued losses, leadership change, and high execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating loss fell from $27M to $11M. |
| Intact |
| operating loss stays above -$11M by 2026-Q1 |
Operating income: $-9.207M FY2026-Q2; GAAP. Published target: operating loss <= -$11M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-9,207,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
maintain Nasdaq listing and avoid delisting notices | A primary condition in Jasper Therapeutics Inc's published investment case. The stated target is no delisting notice or transfer of listing. | Under Pressure | receipt of a delisting notice or failure to meet listing rules | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.16 → $-0.52 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.16 | $173,800 | 3 / 4 |
| 2026-07-25 | $-1.16 | $173,800 | 3 / 4 |
| 2026-07-26 | $-1.16 | $173,800 | 3 / 4 |
| 2026-07-27 | $-1.16 | $173,800 | 3 / 4 |
| 2026-07-28 | $-1.16 | $173,800 | 3 / 4 |
| 2026-07-29 | $-2.56 | $0 | 1 / 4 |
| 2026-07-30 | $-2.56 | $0 | 1 / 4 |
| 2026-07-31 | $-2.56 | $0 | 1 / 4 |
| 2026-08-01 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-02 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-03 | $-2.56 | $0 | 1 / 4 |
| 2026-08-04 | $-2.56 | $0 | 1 / 4 |
| 2026-08-05 | $-2.56 | $0 | 1 / 4 |
| 2026-08-06 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-07 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-08 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-09 | $-2.56 | $0 | 1 / 4 |
| 2026-08-10 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-12 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-13 | $-2.56 | $0 | 1 / 4 |
| 2026-08-14 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-15 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-16 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-17 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-18 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-19 | $-1.16 | $173,800 | 3 / 4 |
| 2026-08-20 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-21 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-22 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-23 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-24 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-25 | $-0.98 | $173,800 | 3 / 5 |
| 2026-08-26 | $-0.53 | $173,800 | 3 / 5 |
| 2026-08-27 | $-0.53 | $173,800 | 3 / 5 |
| 2026-08-28 | $-0.53 | $173,800 | 3 / 5 |
| 2026-08-29 | $-0.72 | $173,800 | 3 / 5 |
| 2026-08-30 | $-0.72 | $173,800 | 3 / 5 |
| 2026-08-31 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-01 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-02 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-03 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-04 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-05 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-06 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-07 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-08 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-09 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-10 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-11 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-12 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-13 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-14 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-15 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-16 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-17 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-18 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-19 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-20 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-21 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-22 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-23 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-24 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-25 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-26 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-27 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-28 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-29 | $-0.72 | $173,800 | 3 / 5 |
| 2026-09-30 | $-0.72 | $173,800 | 3 / 1 |
| 2026-10-01 | $-0.72 | $173,800 | 3 / 1 |
| 2026-10-02 | $-0.72 | $173,800 | 3 / 1 |
| 2026-10-03 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-04 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-05 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-06 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-07 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-08 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-09 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-10 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-11 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-12 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-13 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-14 | $-1.07 | $173,800 | 3 / 1 |
| 2026-10-15 | $-0.52 | $173,800 | 3 / 1 |
| 2026-10-16 | $-0.52 | $173,800 | 3 / 1 |
| 2026-10-17 | $-0.52 | $173,800 | 3 / 1 |
| 2026-10-18 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-19 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-20 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-21 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-22 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-23 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-24 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-25 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-26 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-27 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-28 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-29 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-30 | $-0.52 | $173,800 | 2 / 2 |
| 2026-10-31 | $-0.52 | $173,800 | 2 / 2 |
| 2026-11-01 | $-0.52 | $173,800 | 2 / 2 |
| 2026-11-02 | $-0.52 | $173,800 | 2 / 2 |
| 2026-11-03 | $-0.52 | $173,800 | 2 / 2 |
| 2026-11-04 | $-0.52 | $173,800 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.